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a b s t r a c t
Althoughmanyeukaryotic proteins havebeen secretedby transfectedbacterial cells, little is knownabout
how a bacterial protein is treated as it passes through the secretory pathwaywhen expressed in a eukary-
otic cell. The eukaryotic N-glycosylation system could interfere with folding and secretion of prokaryotic
proteins whose sequence has not been adapted for glycosylation in structurally appropriate locations.eywords:
lycosylation
rotein secretion
ndoplasmic reticulum
hondroitinase
pinal cord injury
Here we show that such interference does indeed occur for chondroitinase ABC from the bacterium
Proteus vulgaris, and can be overcome by eliminating potential N-glycosylation sites. Chondroitinase ABC
was heavily glycosylatedwhen expressed inmammalian cells or in amammalian translation system, and
this process prevented secretion of functional enzyme. Directed mutagenesis of selected N-glycosylation
sites allowed efﬁcient secretion of active chondroitinase. As these proteoglycans are known to inhibit
regeneration of axons in the mammalian central nervous system, the modiﬁed chondroitinase gene is a
erapypotential tool for gene th
. Introduction
In several situations there is therapeutic potential in directed
ecretion of bacterial proteins from eukaryotic cells. Examples are
he expression of bacterial epitopes for vaccination against bacte-
ial pathogens (Lowrie et al., 1999), the characterisation of bacterial
roteins that stimulate T cells (Wilson et al., 2000), and expression
f bacterial inhibitors of cell proliferation as a potential treatment
or cancer (de la Cueva-Mendez et al., 2003). However, secretion
f such proteins may be compromised by the presence of cryptic
ignals in the bacterial sequence that cause inappropriate modiﬁ-
ations in animal cells, such as N-glycosylation.
In mammalian cells, almost all secreted proteins contain
sn-X-(Ser/Thr) motifs (N-X-S/T) which are N-glycosylated co-
ranslationally in the endoplasmic reticulum, to assist and validate
he correct folding of the protein (Gahmberg and Tolvanen, 1996;
empski and Imperiali, 2002). Although an eukaryote-like N-
lycosylation system exists in the bacterium Campylobacter jejuni
Szymanski and Wren, 2005), most bacteria do not perform this
peration. Therefore, genes from most bacterial species may
ncode N-X-S/T at positions where, if expressed in mammalian
ells, they will be N-glycosylated. Such modiﬁcations could inter-
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fere with enzyme folding, impeding transit through the secretory
pathway, and/or cause loss of activity by alteration of the active
site or by sterically hindering substrate binding. Misfolding of a
protein could also direct it to the proteosome for degradation. It is
therefore likely that efﬁcient secretion of bacterial proteins from
mammalian cells may require selective mutagenesis of potential
N-glycosylation sites if they are present.
We aim to transduce mammalian cells to secrete the bacte-
rial enzyme chondroitinase ABC, with a view to gene therapy to
promote regeneration of neural pathways in the human central
nervous system (CNS), particularly in spinal cord injury. Spinal
cord injuries leave large numbers of people permanently paral-
ysed every year, as the damaged axons fail to regenerate. Injury
causes a glial ‘scar’ to form in the spinal cord, and cells in this scar
zone expressmolecules that are inhibitory to axon regrowth (Silver
and Miller, 2004; Yiu and He, 2006; Kwok et al., 2008). Together
with growth-inhibitory proteins released by degenerating myelin,
these molecules prevent regenerative axon growth and functional
recovery. Measures designed to stimulate regeneration have had
signiﬁcant success in rodentmodels (Silver andMiller, 2004;Ramer
et al., 2005; Thuret et al., 2006; Bradbury and McMahon, 2006;
Open access under CC BY license. Kwok et al., 2008).
A signiﬁcant contribution to axon growth inhibition is made by
chondroitin sulphate proteoglycans (CSPGs) (Kwok et al., 2008).
Thesemolecules, such as neurocan andNG2 (Dou and Levine, 1994;
Levine and Nishiyama, 1996; Bovolenta and Fernaud-Espinosa,
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000; Silver and Miller, 2004; Tan et al., 2006; Yiu and He, 2006),
ave long sulphated glycosaminoglycan (GAG) chains attached to
heir core protein component, and the GAG chains are responsible
or much of the inhibitory activity (Grimpe and Silver, 2004).
Chondroitinase ABC is a bacterial enzyme that degrades these
nhibitory carbohydrate chains. It is active when injected into the
ammalianCNS, as it depletesGAG immunoreactivity surrounding
n injury site and concomitantly generates carbohydrate products
hich are not seen in normal tissue (Moon et al., 2001; Bradbury
t al., 2002; Kwok et al., 2008). The use of chondroitinase promotes
xon regeneration in rats, as demonstrated ﬁrst in the nigrostriatal
ract (Moon et al., 2001) and also in the spinal cord (Bradbury et al.,
002). Repeated injections of chondroitinase at the site of spinal
ord injury promoted extensive regeneration of both corticospinal
nd sensory axons, accompanied by signiﬁcant functional motor
ecovery (Bradbury et al., 2002). These results have been conﬁrmed
nd extended by others (Kwok et al., 2008). Chondroitinase also
nhances axon regeneration in combinationwith grafts of Schwann
ells and/or olfactory ensheathing cells or neural stem/progenitor
ells (reviewed by Kwok et al., 2008).
As well as removing the block to axon regeneration by CSPGs,
hondroitinase may promote recovery by other mechanisms,
ncluding dispersal of other axon-inhibitory molecules, neuropro-
ection (Carter et al., 2008), and sprouting and synaptic plasticity
n spared pathways due to removal of perineuronal nets (Crespo et
l., 2007; Galtrey et al., 2007). Whatever the predominant mech-
nism, chondroitinase is clearly a promising treatment for spinal
ord injury.
However, the use of chondroitinase in human CNS will require
odiﬁcation. Delivery of the enzyme by local injection into the
pinal cord region is technically problematic, for several reasons.
hronic infusionor repeated injectionswouldbe required to relieve
xon growth inhibition for the extended periods needed for func-
ional recovery. Chronic delivery carries risks of tissue damage,
nfection, and immunogenicity. A solution to these problemswould
e to transfect neurons and/or glia at the injury site with a vector
ontaining the gene for chondroitinase, so they secrete the enzyme
hemselves.
Our strategy, therefore, is to modify the bacterial chondroiti-
ase ABC sequence so that mammalian cells synthesise and secrete
ctive enzyme. In this study, we show that N-glycosylation is
ndeed an obstacle to secretion of chondroitinase from transfected
ammalian cells, and that it canbeovercomeby selectivemutation
f key N-glycosylation sites.
. Materials and methods
.1. Initial sequence
The sequence of the gene for Proteus vulgaris chondroitinase
BC was reported by Ryan et al. (1994) (Entrez accession number
AB43331=gi1828877) and conﬁrmed by Prabhakar et al. (2005a).
he encoded sequence was also conﬁrmed from the protein crystal
tructure byHuanget al. (2003). These studies showed that an inde-
endent sequence reported by Sato et al. (1994) contained several
rrors.
We obtained a cDNA for P. vulgaris chondroitinase ABC in a
rokaryotic expressionvector, although thecoding region lackedan
-terminal signal sequence to direct secretion from cells, and had
wo inactivating mutations. Apart from these changes, the clone
ncoded the same sequence reported by Ryan et al. (1994). We cor-
ected the two mutations by site-directed mutagenesis, and added
eukaryotic signal sequence from mouse matrix metalloprotease
(GenBank accession no. NM008610=gi47271505) (Reponen et
l., 1992). An optimised Kozak sequence was also inserted at
he 5′ end to allow recognition by eukaryotic ribosomes and tonology 145 (2010) 103–110
maximise protein yield. We further changed some of the codons
that are unfavourable for translation by mammalian ribosomes,
replacing them with those used more frequently by mammalian
cells. The resulting ‘initial sequence’ is shown in Supplementary
Fig. S1.
This modiﬁed cDNA was subcloned into the eukaryotic expres-
sion vector pcDNA 3.1 (Invitrogen), in which transcription is
directedby thecytomegaloviruspromoter,whichdirectshigh-level
expression in a wide range of mammalian cells. This initial clone is
named C4.
Protein structurewas visualised usingRasMolMolecularGraph-
ics Visualisation Tool (by Roger Sayle: http://www.rasmol.org).
2.2. Site-directed mutagenesis
Mutagenesis was carried out using the QuikChange Multi-Site-
DirectedMutagenesis kit (Stratagene). All mutagenesis was carried
out using constructs inserted in pcDNA 3.1.
Primers containing the desired mutations (Supplementary Fig.
2) were designed where possible to insert or delete a restriction
site to allow easy identiﬁcation ofmutant clones. The primerswere
modiﬁed with a 5′ phosphate and PAGE-puriﬁed to improve muta-
tion efﬁciency. All clones were sequenced to conﬁrm successful
mutagenesis. Each construct was assayed using the TNT system
(below) to assess the effect of the mutation on enzyme activity.
This allows us to distinguish the direct effect of the mutation on
enzyme activity separately from any effects due to glycosylation
inside the cell.
2.3. In vitro transcription–translation
In vitro transcription/translation (IVTT) reactions were car-
ried out with rabbit reticulocyte lysate in a coupled reaction
with T7 polymerase, using the TNT Quick Coupled Transcrip-
tion/Translation kit (Promega). Each 25l reaction contained
1g of plasmid. Labeled reactions also included 1l biotinylated
lysine (Transcend) or 1l 35S-methionine (Redivue l-methionine,
37MBq/mmol, Amersham). Reactions to assess glycosylation also
contained 1l of canine microsomes (Promega). The samples were
incubated at 30 ◦C for 90min. The products of the IVTT reactions
were then separated by sodium dodecyl sulphate polyacrylamide
gel electrophoresis (SDS-PAGE), as follows:
Western blots for chondroitinase ABC: 5l samples were run on
6% reducing gels and blotted as described below.
35S-labeled samples: 5l samples were run on 8% Tris/glycine
gels (Invitrogen), ﬁxed in methanol/acetic acid, and incubated in
Amplify (Amersham) for 30min prior to drying. The dried gelswere
then exposed to X-ray ﬁlm for 2h.
Biotin-labeled samples: 1–2l samples of IVTT reactions labeled
with biotinylated lysine were run on 10% Tris/glycine gels,
transferred to nitrocellulose membrane using a semi-dry-blot
(Invitrogen), and then probed with strepavidin-linked horse radish
peroxidase (Promega), prior to development using chemilumines-
cence (Promega). All chemiluminescence products were detected
using chemiluminescence ﬁlm (Amersham).
Protease protection assay (Schmidt-Rose and Jentsch, 1997): The
translation mixture was brought to 10mM CaCl2 and chilled on
ice. Aliquots of 10l were incubated with Proteinase K, 30g/ml
(Roche), in the presence or absence of 1% Triton X-100. Controlson ice for 60min and was stopped by adding 5mM phenyl-
methylsulphonyl ﬂuoride. After 10min on ice, 50l of preheated
sample buffer (95 ◦C) was added and the sample was boiled for
15min to inactivate the protease. The samples were then run on
a gel.
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.4. Morgan–Elson reaction
This reaction measures chondroitinase activity by the N-
cetylation of product disaccharides and subsequent reaction
o give a coloured product (Morgan and Elson, 1934; Reissig
t al., 1955). The procedure was adapted from one given at
http://www.acciusa.com/seikagaku/products/product.asp>.
Initially the reaction resulted in unstable colour intensity due to
he formationofprecipitateduring the reaction, aspreviouslynoted
Takahashi et al., 2003). Therefore, activity could only be estimated
ualitatively.We then reﬁned the procedure by centrifuging at two
tages to minimise the presence of precipitate at the end, thereby
llowing spectrophotometry to be used to quantify activity.
The reaction mixture was made up of 100l of 40mM sodium
cetate, 40mM Tris–Cl pH 8.0, 10mg/ml chondroitin-6-sulphate
Sigma), mixed with 20l enzyme sample (IVTT product or stan-
ard). P. vulgaris chondroitinase ABC (Sigma) was used as standard.
he reaction was incubated at 37 ◦C for 20min, then stopped
y boiling for 1min. Potassium borate solution (0.8M, pH 9.1,
00l) was added and the mixture was boiled for 7min. It was
hilled on ice then centrifuged in a microfuge at 13,000 rpm for
0min. To the supernatant, 1ml glacial acetic acid was added
nd mixed before centrifugation for a further 20–30min. To
ml of supernatant, 0.4ml of Morgan–Elson Reagent (10g para-
imethylamino-benzaldehyde in 100ml in glacial acetic acid with
2.5% concentrated HCl) was added and incubated at 37 ◦C for
0min. Product was measured by absorbance at 550nm. (This
avelength gives higher and more consistent absorption values
han the standard 585nm.)
.5. Cell culture and transfection
Neu7 cells (Smith-Thomas et al., 1994; Fok-Seang et al., 1995)
ere grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) con-
aining 10% fetal bovine serum and 10% horse serum. When cells
ad just reached conﬂuence, the medium was replaced by DMEM
ith ITS3+, for 48h, providing conditionedmediumforuseon trans-
ected cells.
COS7 cells were grown in Optimem (Gibco-Invitrogen) with
0% fetal bovine serum. Media for all cell cultures were supple-
ented with standard concentrations of penicillin, streptomycin
nd fungazone.
Primary glial cells were cultured from cortex of Wistar rat pups
–2 days old (Muir et al., 2002), grown in DMEM with 10% fetal
ovine serum, passaged after about one week (leaving a culture
onsisting mainly of astrocytes), and used for transfection several
ays later.
Transfection was performed in 25-cm2 ﬂasks with the cells
60–70% conﬂuent, with polyethyleneimine (PEI) or FuGene, and
AdVAntage vector to increase translation efﬁciency (Promega),
sing standard procedures. After 24h, the medium was replaced
ith Neu7 conditioned medium. This conditioned medium was
ollected after 24h, centrifuged to remove detached cells, and
oncentrated 5–10-fold by centrifugation in a Centricon-50 unit
Millipore), mixed with protease inhibitor cocktail (Sigma P8340),
nd frozen for subsequent electrophoresis.
In every round of transfections, one transfection was per-
ormed with GFP to assess transfection efﬁciency by ﬂuorescence
icroscopy of the live cells, and in some cases by ﬁxation and
ounterstaining with bisbenzamide (Hoechst 33258). Transfection
fﬁciencies were 17–50% for COS cells..6. Western blots
Sodium dodecyl sulphate polyacrylamide gel electrophore-
is (SDS-PAGE) and Western blotting were done by standardnology 145 (2010) 103–110 105
techniques. For detection of proteoglycans, samples of concen-
trated conditioned medium were either 50l or the volume
containing 200g protein. Controls were similar samples from
non-transfected cells, one of which was digested with chondroiti-
nase ABC (Sigma, 20mU) at 37◦ for 3h. Samples were mixed with
10l of 5× non-reducing Laemmli sample buffer, boiled for 2min,
separated by SDS-PAGE (5% acrylamide gel), and electroblotted in
a Transblot Semi-dry Transfer Cell blotter (Bio-Rad) to Hybond-ECL
membrane.
IVTT product samples consisted of 5l IVTT product, 6l
5× reducing Laemmli sample buffer, 19l chondroitinase buffer
(40mM NaAc, 40mM Tris–Cl pH 8.0). Proteins were separated
by SDS-PAGE (6% acrylamide gel) and transferred to Hybond-ECL
membrane.
Antibodies were: mouse anti-NG2 (Santa Cruz sc33666=mcAb
132.38), diluted 1:1000; mouse anti-‘stub’ (Seikagaku, mcAb 1B5,
1:250); rabbit anti-chondroitinase ABC (Acorda Inc., 1:2000, pre-
absorbed by incubation with conditioned medium from Neu7 cells
for 3h at room temperature). The anti-‘stub’ antibody detects an
epitope revealed by chondroitinase action, remaining attached to
theCSPGcoreproteins as a so-called ‘stub’ after chondroitinaseABC
has cleaved off most of the CSPG chains. The CSPG repeating dis-
accharide unit, d-glucuronic acid linked to N-acetyl-galactosamine
(variously sulphated), is masked in native CSPG, but is revealed
after chondroitinase digestion. Chondroitinase ABC is largely spe-
ciﬁc for sulphated units, and antibody 1B5 (Couchman et al., 1984)
recognises the unsulphated unit (-di-0S) that remains behind,
thus acting as a sensitive probe for chondroitinase activity.
Membranes were incubated in 2% ECL Advanced Blocking Agent
(Amersham) in Tris-buffered saline with 0.1% Tween-20 (TBS-T) at
room temperature for 3–4h, then incubatedwith primary antibody
in blocking solution, overnight at 4 ◦C. Membranes were washed
in TBS-T before incubation with secondary antibody (peroxidase-
labeled anti-mouse or anti-rabbit IgG, 1:10,000 to 1:30,000 in
blocking solution) for 1h at room temperature. Membranes were
washed in TBS-T before reaction with ECL chemiluminescence
detection reagent and visualisation on Hyperﬁlm (Amersham).
3. Results
3.1. Recombinant chondroitinase ABC is active in vitro
We constructed a cDNA clone that encodes the natural (bac-
terial) sequence of chondroitinase ABC, with a Kozak sequence
to initiate translation in mammalian cells, and the mouse MMP2
signal sequence to direct secretion of the enzyme, and some
codons modiﬁed to be more favourable for mammalian expression
(sequence in Supplementary Fig. S1; see Section 2). This ‘initial’
cDNA, subcloned into the expression vector pcDNA 3.1, was named
clone C4.
This vector was sufﬁcient for active enzyme to be produced
when testing the construct in an in vitro transcription/translation
(IVTT) system using rabbit reticulocyte lysate, followed by protein
gel electrophoresis. A protein of the expected sizewas synthesised;
it was immunoreactive with antibody against chondroitinase ABC;
and active enzyme could be detected by colorimetric assay. How-
ever, no secreted enzyme activity was detected after transfection
of COS7 cells with the construct, even though RT-PCR conﬁrmed
that the cDNA was efﬁciently transcribed by the cells (data not
shown).
One explanation for the lack of detectable secreted product
may be the presence of cryptic signals in the bacterial protein
which are inappropriately recognised and processed by eukaryotic
cells. Computer prediction programs established the absence of the
endoplasmic reticulum retention signal KDEL and signal sequences
directing proteins to organelles, but we did ﬁnd 17 predicted sites
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Table 1
Mutations of N-glycosylation sites.
Clone number: C4 B5 B1 X12 X30 Y13 B2 Y133 A10 A106
Positions changed: 0 1 2 3 3 4 5 5 5 4
Asn-751 – N-Q N-Q N-Q N-Q N-Q N-Q N-Q N-Q -
Asn-515 (S-A) – S-A S-A S-A S-A S-A S-A S-A S-A
Asn-345 – N-Q N-Q N-Q N-Q N-Q N-Q
Asn-338 – N-Q N-Q
Asn-282 – N-K N-K N-K N-K N-Q N-Q
Asn-675 – N-Q
Asn-836 – N-D
++ ++ ++ +++ ++ ++
T Thr) sites. Mutations were Asn-Gln (N-Q), Asn-Lys (N-K), Asn-Asp (N-D), or Ser-Ala (S-A;
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Our hypothesis is that these sites are being inappropriately gly-
cosylated in a eukaryotic system. To test this, and identify whichActivity after transfection: – (+/−) + ++
he table indicates whether each clone had a mutation at each of seven Asn-X-(Ser/
t position +2 relative to the Asn), as indicated.
or N-glycosylation in the protein sequence. Such modiﬁcations
ould interfere with enzyme folding and/or transit through the
ecretory pathway.
A protein 3D-imaging program was used to locate the poten-
ial N-glycosylation sites, and found several in regions very likely
o affect protein folding and/or substrate binding (Fig. 1). We per-
ormed multi-site-directed mutagenesis on seven sites (Fig. 1;
able 1; Supplementary Figs. S2 and S3). Glycosylation recognition
equences were abolished by conservative substitutions, in most
ases Asn→Gln.
.2. Mutations at most N-glycosylation sites do not impair
nzyme activity in vitro
The different constructs were tested for activity by transcrip-
ion and translation in the rabbit reticulocyte lysate system (IVTT),
nd the products assayed by the colorimetric assay (Morgan–Elson
eaction). All constructs produced similar amounts of protein. This
as demonstrated either by Western blot using an antibody to the
acterial enzyme (Fig. 2), or by labeling the products with biotiny-
ated lysine or 35S-methionine (Fig. 3a).All the clones listed produced similar levels of activity in the
organ–Elson reaction (data not shown). Onemutation, Thr 340 to
la, however abolished enzyme activity but the alternative muta-
ion, Asn 338 to Gln, was well tolerated. Thus it is possible to make
he required changes without compromising enzyme activity.
ig. 1. 3D structure of bacterial chondroitinase ABC, showing putative glycosylation
ites that have been eliminated. The structure is from Huang et al. (2003). The active
ite is on the right-hand ﬂank of the cleft (Prabhakar et al., 2005b). Six potential N-
lycosylation sites predicted to affect enzyme structure or activity are highlighted.
ifferent constructs differ as follows (see Table 1): B5 v C4, Asn 751; B1 v B5, Asn
15; X12 v B1, Asn 345; X30 v B1, Asn 282; and Y13 v A10, Asn 338. (A seventh site,
sn-836, was mutated in one clone but is not glycosylated.) See Supplementary Fig.
3 for coloured version.Fig. 2. Western blot of products of the IVTT reactions detected with anti-
chondroitinase antibody. Left, commercial chondroitinase ABC; right, IVTT products
from the six clones indicated. The products comigrate with commercial chondroiti-
nase ABC, and similar amounts are produced by all clones.
3.3. Mutations at N-glycosylation sites reduce glycosylation inFig. 3. SDS-PAGE of IVTT reactions with microsomes to assess glycosylation. IVTT
reactions were labeled with 35S-Met (a and c) or biotinylated lysine (b) and incu-
bated with canine microsomes. After SDS-PAGE and blotting, the products were
visualised. (a) Products of different clones. The lower arrow indicates unglycosy-
lated chondroitinase ABC, which comigrated with commercial chondroitinase (not
shown); the upper arrow indicates the upper (glycosylated) band, which was not
produced without microsomes (lane 1). The glycosylated band migrates faster in
products of clones with several mutations of N-glycosylation sites. (b) Conﬁrma-
tion that the upper band is protected from Proteinase K, indicating that it has been
internalised in the microsomes (clone C4). Lane 1, IVTT with microsomes; Lane 2,
the same plus Proteinase K; Lane 3, the same plus Triton X-100 to lyse the micro-
somes. (c) Conﬁrmation that the upper band is digested by N-glycosidase (clone
C4). Lane 1, IVTT with microsomes; Lanes 2 and 3, the same plus N-glycosidase
(1g, 10g); Lane 4, IVTT without microsomes. (Lanes 1 and 2 are shown at higher
contrast because they contained less material.)
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Fig. 4. Chondroitinase ABC with reduced N-glycosylation is secreted in active form from transfected cells. Neu7 conditioned medium (a source of CSPGs) was placed on
transfected cells for 24h, then analysed by Western blotting, with antibodies against (a) the CSPG, NG2; (b) carbohydrate stubs produced by chondroitinase action (antibody
1B5); (c) chondroitinase ABC. Each lane is labeled according to the clone used for transfection, with the number of mutated glycosylation sites listed below. In (a, b, c and
g), the ﬁrst two lanes are positive and negative controls with Neu7 medium not exposed to transfected cells. Samples marked “+Ch’ase” were digested with commercial
chondroitinase in vitro before SDS-PAGE. (a) Probed for NG2. Lanes 1 and 2, controls: in medium from untransfected cells, NG2 appears largely as a characteristic ‘smear’
as expected due to the GAG chains (lane 2), and this is all converted to core protein by digestion with commercial chondroitinase (lane 1). Lanes 3 and 4: No change in
medium incubated with COS7 cells transfected with initial clone C4 or B5. Lane 5: With mutant Y13, chondroitinase activity eliminates the GAG chain smear and all NG2
appears as core protein. (b) Probed for 1B5 stub epitope. Neu7 conditioned medium, and the same incubated with GFP-transfected COS7 cells, shows little immunoreactivity
(lanes 2 and 3), but digestion with commercial chondroitinase in vitro generates extensive reactivity (lane 1). Lanes 4–6: Medium incubated with COS7 cells transfected with
chondroitinase mutants; all generate immunoreactivity, maximal for clone B2. (c) Same blot re-probed for chondroitinase ABC. Commercial chondroitinase (lane 1) shows
both full-length band (Ch) and a shorter band (Ch**) due to proteolytic activity during incubation with medium. Clones X12, B1, and B2 all generate a diffuse chondroitinase
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ommercial chondroitinase. (e and f) Blots of additional clones, probed for NG2 (e) a
o clone Y133 (the most active of all). (g) The same experiment with transfected Ne
etween gels, the activity rankings in Table 1 are the consensus of several experime
f the sites are actually glycosylated, we compared different con-
tructs in the reticulocyte lysate system in the presence of canine
icrosomes (endoplasmic reticulum preparation), which incorpo-
ate and N-glycosylate the nascent polypeptide as in an animal
ell.
The unmodiﬁed enzyme (C4) was heavily glycosylated in the
resence of microsomes (Fig. 3a, lane 2). The unglycosylated form
roduced in the absence of microsomes was seen as a band of
round 110kDa. In the presence of microsomes, an additional band
as seen at higher Mr, as expected for glycosylation. To conﬁrm
hat it was internalised by the microsomes, a Proteinase K protec-
ion experiment was performed (Fig. 3b). N-linked glycosylation
ccurs only within intact microsomes, and this assay makes use
f the protection afforded the translocated protein domain by the
icrosomal membrane. Thus, translocated proteins are protected
rom exogenously added protease, and only the glycosylated form
emains. To conﬁrm that it was indeed glycosylated, samples were
igestedwithN-glycosidase (Fig. 3c, lanes2 and3), and thehigh-Mr
and disappeared as expected.
The glycosylated products of clones C4 and B5 comigrate
Fig. 3a), so the mutation of Asn-751 in B5 made no visible dif-
erence to the glycosylation. This indicates that Asn-751 is not
etectablyglycosylated, consistentwith the sequenceﬂankingAsn-
51 which makes N-glycosylation unlikely (Petrescu et al., 2004).
onversely, the glycosylated products of clones with mutations at
ther sites show increasedmobility on the gel (Fig. 3a). Comparison
f these products with the mutations they contain (Table 1) indi-
ates that Asn-675, 515, 345, 338 and 282 are all glycosylated as
redicted. The glycosylation of Asn-515 is of particular signiﬁcance
ecause it lies in the cleft which constitutes the enzyme’s active
ite.-glycosidase (lane 2). The diffuse band collapsed to a sharp band of the same Mr as
1B5 stub (f). These blots show a range of activity from clone B5 (little or no activity)
d SCTM41 cells, probed for 1B5 stub epitope. As the intensity of 1B5 staining varies
which subsets of clones were compared on single gels.
Similar experiments with other constructs (not shown) have
shown that Asn-856 and 963 are also glycosylated, but Asn-836
is not. Thus 7 out of 9 sites so far tested are glycosylated as
predicted.
3.4. Chondroitinase ABC with reduced N-glycosylation is secreted
in active form from transfected cells
To test for secretion of active chondroitinase, we transfected
each of the constructs into COS7 cells, and assayed conditioned
medium by Western blotting for the effect of chondroitinase on
CSPGs. These cells do not synthesise signiﬁcant amounts of CSPGs,
so as a source of CSPGs we incubated the cells after transfection
with conditioned medium from the Neu7 cell line. These astrocyte-
like cells (Fok-Seang et al., 1995) secrete substantial amounts of
the axon-inhibitory CSPG, NG2, into the medium and the matrix
(Smith-Thomas et al., 1994; Fidler et al., 1999). NG2 comprises a
core protein of ∼290kDa, and a proportion of the molecules are
glycanated and therefore run as a higher-Mr smear on a gel (Levine
and Nishiyama, 1996). Chondroitinase activity is demonstrated by
reduction or loss of the glycanated smear, which is converted into
the core protein. Therefore to assess chondroitinase activity, we
applied Neu7 conditioned medium to the transfected COS7 cells
from 24h to 48h post-transfection, then analysed the medium by
Western blotting for NG2 (Fig. 4a).
In addition, blots were probed with the antibody 1B5, which
recognises a carbohydrate ‘stub’ epitope that remains on the core
proteins after chondroitinase has cleaved off the CSPG chains
(Fig. 4b). This is a sensitive marker of chondroitinase activity as it
detects the appearance of a novel product rather than the diminu-
tion of a substrate.
1 iotechnology 145 (2010) 103–110
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The Western blots (Fig. 4a, b, e and f) showed that the initial
lone C4 (encoding unmodiﬁed bacterial chondroitinase) had no
ctivity, but in contrast clone B1, with two N-glycosylation sites
utated, had signiﬁcant activity as shown by both antibodies.
lones with three or more sites mutated had even more activity:
hey produced complete degradation of the NG2 GAG chains, and
hey produced levels of stub reactivity comparable with in vitro
reatment with commercial chondroitinase ABC.
The same blots were re-probed with antibody against chon-
roitinase (Fig. 4c). A diffuse band was seen which represents
artially glycosylated chondroitinase. Its identity was conﬁrmed
y N-glycosidase digestion in vitro, which converted it to a sharp
and that comigrated with commercial chondroitinase (Fig. 4d).
he initial clone C4 produced a variable amount of this band, or
one, suggesting that glycosylation of the unmodiﬁed sequence
nterfered with secretion to a variable extent, but any protein pro-
uced was always inactive. Clones which produced chondroitinase
ctivity in the medium always produced this chondroitinase band,
nd its mobility was slightly faster for clones that produced more
ctivity, conﬁrming that the additional mutations in those clones
ad further reduced the amount of N-glycosylation of the enzyme.
Additional clones are shown in Fig. 4e and f, including the clone
ith the highest activity obtained so far, clone Y133, which has
utations at 5 N-glycosylation sites. The results from all experi-
ents are summarised in Table 1.
To test for activity in cells of nervous system origin, we trans-
ected two glial cell lines: SCTM41 cells derived fromSchwann cells
Wilby et al., 1999), and Neu7 cells derived from astrocytes. Again,
edium from conﬂuent Neu7 cells was added as a source of CSPGs
since newly transfected Neu7 cells do not synthesise signiﬁcant
mounts of CSPGs for 48h after transfection; data not shown). The
esults were similar to those with COS7 cells (Fig. 4g), conﬁrm-
ng that the unmodiﬁed sequence C4 was inactive but modiﬁed
equences Y13 and especially Y133 were active. The same result
as obtained with primary astrocytes from neonatal rat cortex
Fig. 5).
. Discussion
In this study, we have shown that bacterial chondroitinase is
nappropriately glycosylated by mammalian cells and that this has
detrimental effect on secretion of active enzyme, which can be
vercome by removing strategic glycosylation sites.
The occurrence of N-glycosylation was demonstrated ﬁrst
sing in vitro transcription–translation. In the presence of micro-
omes, chondroitinase synthesised from all our constructs was
nternalised (proteinase-protected) and N-glycosylated (slower-
igrating). Clones with glycosylation site mutations produced
aster-migrating bands, conﬁrming that the glycosylation was
educed as intended.
Secretion of N-glycosylated chondroitinase by transfected COS7
ells was investigated by Western blots. The initial clone C4
encoding the native bacterial sequence) produced either glyco-
ylated chondroitinase or none. This stochastic behaviour could be
xpected if the block to secretion is self-amplifying, and thus sensi-
ive to slight ﬂuctuations in the initial impairment in the secretory
athway. The block might be initiated by exposure of hydrophobic
equences, or aggregation of misfolded protein, or inappropriate
nteraction with the secretory machinery. Any secreted chon-
roitinase from this clone lacked detectable enzymatic activity.
ikewise clone B5, with only one mutation, produced secreted
ut inactive protein. Thus the secreted protein was in an inac-
ive form, presumably due to carbohydrate chains either distorting
he protein structure or producing steric hindrance of the active
ite. We conclude that the initial sequence allowed internalisation
nd glycosylation in the ER, but variably impeded transit throughprimaryastrocytes. The sameexperiment as in Fig. 4,with transfectedprimaryastro-
cytes, probed for NG2, 1B5 stub epitope, and chondroitinase ABC. Again, clone C4 is
inactive and clone Y133 is highly active.
the secretory pathway, and invariably blocked secretion of active
enzyme.
We then showed that ablation of strategic glycosylation sites
resulted in secretion of active enzyme from transfected cells.
Enzyme activity was demonstrated by two Western blot assays for
degradation of CSPG GAG chains in the medium. As the experiment
usedpre-conditionedmediumas theonly sourceof CSPGs, this con-
clusively showed that the chondroitinase was secreted and acting
extracellularly.
The improvement in secreted activity was attributable to the
change in glycosylation, rather than to any changes in translation
efﬁciency of the gene, given that the least-modiﬁed clones could
secrete detectable but inactive enzyme (above), and the activity of
the enzymes following transfection correlated with the number of
glycosylation sites that had been ablated (Table 1). Clone B5, with
only Asn-751 mutated, was still essentially inactive. Clone B1 (two
sites mutated) showed some activity. Clones with three or more
sitesmutatedall showedstrongactivity, comparable to thatof com-
mercial chondroitinase. The most active is clone Y133, which also
produces the largest amount of chondroitinase immunoreactivity
in conditioned medium.
It is likely that the effect is due to several speciﬁc sites, rather
than merely the number of sites mutated. Asn-751 may be imma-
terial, as it is unlikely to be N-glycosylated at all according to the
rules of Petrescu et al. (2004), and our in vitro assay showed that
deleting this site had no effect on the mobility of the glycosylated
protein (Fig. 4, clone B5). Conversely, Asn-515 seems to be impor-
tant as it lies in the active site. We conclude that the mutations
required for efﬁcient secretion of active enzyme (yielding activity
similar to the commercial enzyme) are those eliminating glycosy-
lation at Asn-282, 336, 345, and 515, and that mutation of Asn-675
increases the activity still further.
It is important to identify these individual sites where N-
glycosylation is deleterious. It is also important to test mutants in
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itro to determine whether the enzyme activity has been compro-
ised before they can be tested for secretability. For example a
hr-Ala substitution at Thr-338 abolished activity in the in vitro
ssay (data not shown), whereas a mutation at Asn-336, eliminat-
ng the same N-glycosylation site, was well tolerated. In addition,
e have mutated other potential N-glycosylation sites and found
hat some changes actually prevent the secretion of the enzyme
unpublished data).
Cafferty et al. (2007) have reported production of Proteus chon-
roitinase ABC in transgenic mice, using the GFAP promoter and
heoriginal bacterial signal sequence to express it in astrocytes, and
emonstrating activity in the injured CNS by staining with a stub
ntibody. However the stub antibody can detect small amounts of
hondroitinase product, and indeed it could have detected prod-
ctsof intracellular chondroitinaseactivityonnascentCSPGswhich
ad subsequently been secreted. Thus, efﬁcient secretion of the
nzyme was not proven. Moreover, the astrocytic expression was
ot sufﬁcient to allow corticospinal axons to regenerate beyond the
esion, unlike the injection experiments of Bradbury et al. (2002),
nd neuronal expression was not attempted. As we have shown
hat mutations of glycosylation sites are required to achieve secre-
ion of active enzyme in cultured cells, it is clearly important to
se these mutants in future transgenic experiments for optimal
xpression.
Curinga et al. (2007) have recently reported expression of a dif-
erent bacterial enzyme, chondroitinase AC, in mammalian cells,
sing an immunoglobulin signal sequence and adenovirus vec-
or. However the speciﬁc activity of the secreted product was
ow.
This work extends our knowledge of the conditions required to
xpress bacterial proteins in eukaryotic cells, highlighting one of
he cryptic signals that may be recognised in bacterial sequences.
his may now be applied to other situations where bacterial pro-
eins need to be expressed by eukaryotic cells.
Bacterial chondroitinase ABC has shown considerable promise,
treatment for spinal cord injury. A gene expressing it in secretable
orm could be transfected into cells for grafting into the CNS injury
ite (e.g. Wilby et al., 1999). It could also be expressed from viral
ectors to target it to neurons and/or glia in the injured CNS. These
oals now appear achievable given that ablation of strategic glyco-
ylation sites results in secretion of active enzyme.
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